Abstract: A novel Trichoderma harzanium strain, filed on Jun. 12, 2018 with the CNCM (Collection Nationale de Cultures de Micro-organismes), 25-28 rue du Docteur Roux, 75724 Paris Cedex 15, under number CNCM I-5327. Also, the use of this Trichoderma harzanium strain to control fusarium head blight in cereals selected from wheat, Brachypodium distachyon, triticale, oats and rye, and more particularly to combat fusarium head blight in wheat.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Abstract: The present disclosure relates to the use of mesoporous solids to control relative humidity in enclosed spaces while greatly reducing energy expenditure. The mesoporous solids are particularly suitable for controlling relative humidity in greenhouses.

Abstract: The present invention relates to the use of a sequence chosen among Seq ID No 3, Seq ID No 1, Seq ID No 2, Seq ID No 4, Seq ID No 5, Seq ID No 6, Seq ID No 7, Seq ID No 8, and functional variants thereof, as an odorant binding protein (OBP).

Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

Abstract: The present invention particularly relates to a method for physical vacuum deposition of a coating (R) comprising at least one material (M) on at least a portion of a front face (10) of a support (1), said at least one material (M) originating from an evaporation source or an atomisation source (2), wherein: —use is made of a support (1), at least a portion of the front face (10) of which is smooth, that is to say, does not have any roughness and/or reliefs and/or recesses; —said vacuum deposition is carried out while varying the thickness distribution of the material (M) on said front face (10), that is, while progressively varying the thickness deposited, from a central region (11) in the direction of at least one lateral region (12) contiguous to the central region (11), without modifying the position of the evaporation source or atomisation source (2) of the material particles (M).

Abstract: The invention relates to a method for coating a textile material, said method comprising the following steps: a) at least one cycle of impregnating the textile material with a sol-gel adhesion formulation, said sol-gel adhesion formulation being free of polycarboxylic acid; b) at least one cycle of drying the impregnated textile material obtained in step a); c) at least one cycle of impregnating the dried textile material obtained in step b) with an omniphobic or hydrophobic sol-gel formulation comprising sulphamic acid, said omniphobic or hydrophobic sol-gel formulation being different from the sol-gel adhesion formulation; d) at least one cycle of drying the impregnated textile material obtained in step c).

Abstract: Enzyme-triggered self-reacting arm compounds and chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. A Ligand-Drug-Conjugate (LDC) includes such enzyme-triggered self-reacting arms.

Abstract: The invention relates to a process for nanostructuring the surface of a solid material in order to form a regular pattern of nanostructures on said surface, comprising: irradiating the surface by a plurality of pulse trains (20) of a femtosecond laser beam: each pulse train (20) comprises at least two pulses (21, 22), each pulse has a peak fluence, and a sum of the peak fluences of the pulses of a pulse train is between 10% and 70% of a threshold fluence corresponding to a material ablation threshold for one pulse for said material, two consecutive pulses of a pulse train are separated by a peak-to-peak duration ?T between 500 fs and 150 ps, two consecutive pulse trains are separated by a duration greater than 10 ?T, obtaining a regular pattern of nanostructures on said portion of surface, having a spatial periodicity lower than 130 nm.

Abstract: The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is an amatoxin, particularly ?-amanitin.

Abstract: A method of manufacturing a composite material including at least one ply integrating at least one electronic element situated at the surface of the ply. Also, materials obtained thereof and devices including such materials. The method includes: a) preparing or providing a first substrate having at least one layer; b) applying at least one electronic element onto a face of the first substrate; c) at least partially impregnating the so-obtained product within an impregnation material to form a matrix incorporating the at least one electronic element and the first substrate; d) preparing or providing an impregnable second substrate, the second substrate being placed on top of the impregnated at least one electronic element so that the at least one electronic element is interposed between the first substrate and the second substrate; e) removing the first substrate from the impregnated product obtained; and f) recovering the composite material.

Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110? and/or p110? inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.

Abstract: The present invention relates to an antibody -drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.

Abstract: A lifetime optimization method for a two-sided photovoltaic module, which includes at least one multi-junction stack, where the stack's first junction layer is on the module's first side, which is exposed to the sun at the beginning of the module's life in the module's base position, and the stack's last junction layer is arranged under the module's second side, which receives diffused and reflected light and light passed through the stack. The method includes measuring the full module's output power (PFM); calculating an estimated output power for the last junction layer (PLL) as a function of the first irradiance in the module's turned over position, where the second side becomes its upper side; comparing the estimated PLL with the PFM when the first side is the upper side and recommending turning over the module when the base position's PFM becomes less than the turned over position's estimated PLL.

Abstract: A composition of yeast polysaccharides including ?(1,6)-glucans, preferably also mannans and ?-glucans. The yeast polysaccharides are extracted from yeast cell wall fragments. Typically, the ?-glucans are ?(1,6)-glucans. Also, a method for obtaining such a composition, including at least one step of fractionating a composition of yeast cell walls and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). Further, a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms, as well as to its non-therapeutic use for improving intestinal comfort.

Abstract: Method for estimating an axial power imbalance in a nuclear reactor, comprising the following steps: obtaining a reactor power setpoint, for each variable of a plurality of variables of the reactor, determining a sequence of the variable, the sequence representing estimated future variations of the variable, determining a sequence of the axial power imbalance, by taking into account the sequences of the plurality of variables of the reactor, the determination of the sequence of the axial power imbalance using a machine learning module that is trained beforehand on historic reactor data.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Abstract: The present invention relates to the use of a sequence chosen among Seq ID No 3, Seq ID No 1, Seq ID No 2, Seq ID No 4, Seq ID No 5, Seq ID No 6, Seq ID No 7, Seq ID No 8, and functional variants thereof, as an odorant binding protein (OBP).

Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.

Abstract: An optical structure comprising at least one stack having a central filter (1) and two sandwiching optical elements (2,3) between which the central filter (1) is interposed, wherein the central filter (1) is in a matrix material. The matrix material being doped with at least one doping agent, the central filter (1) and the two optical elements (2,3) on either side thereof being assembled by bonding layers (4a, 4b) of a material based on the same matrix material as that of the central filter, the optical elements (2,3) on either side of the central filter (1) and the bonding layers (4a, 4b) each having a refractive index equal to that of the material of the central filter or only differing from this refractive index within a range of plus or minus 0.05, preferably within a range of plus or minus 0.02.